A5059495420- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Treatment and Management
- Risk Management in Financial Firms
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Pharmaceutical Economics and Policy
- Pharmaceutical industry and healthcare
- Law, logistics, and international trade
Health Sciences Authority
2017-2020
As of December 2017, 20 diabetic ketosis (DK)/diabetic ketoacidosis (DKA) cases associated with sodium–glucose co-transporter 2 inhibitors (SGLT2i) had been reported to the Health Sciences Authority (HSA), Singapore. We aimed provide a detailed analysis profile these cases. part emerging safety issue monitoring, HSA followed up on SGLT2i-associated DK/DKA reporters obtain missing and/or supplementary information. Descriptive statistics were employed summarise data collected, while...
Background: Effective benefit–risk communication to healthcare professionals plays a vital role in promoting the rational use of medicinal products. The Health Sciences Authority (HSA) Singapore has implemented Physician Educational Materials (PEMs) and Patient Medication Guides (PMGs) as educational materials support informed decision-making. To evaluate their effectiveness safety tool, we sought understand prescribers’ experiences preferences with these materials. Methods: Invitations an...